By Conjoint Professor David goldstein

Journal articles

Dear AE; Goldstein D; Hayman JA, 1996, 'Malignant pulmonary lymphoid disease: Case reports illustrating anatomical pattern of disease as a prognostic marker', Pathology, 28, pp. 20 - 24, http://dx.doi.org/10.1080/00313029600169443

Newell M; Goldstein D; Milliken S; Lewis C; Hoy J; Thomson B; Cooper D, 1996, 'Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma', Annals of Oncology, 7, pp. 1029 - 1036, http://dx.doi.org/10.1093/oxfordjournals.annonc.a010495

Millward MJ; Bishop JF; Friedlander M; Levi JA; Goldstein D; Olver IN; Smith JG; Toner GC; Rischin D; Bell DR, 1996, 'Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer', Journal of Clinical Oncology, 14, pp. 142 - 148, http://dx.doi.org/10.1200/JCO.1996.14.1.142

Goebel F; Goldstein D; Goos M; Jablonowski H; Stewart JS, 1996, 'Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi`s sarcoma', British Journal of Cancer, 73, pp. 989 - 994, http://dx.doi.org/10.1038/bjc.1996.193

Nirenberg A; Meikle GR; Goldstein D; Meikle RG, 1995, 'Metastatic carcinoma infiltrating lung mimicking BOOP', Australasian Radiology, 39, pp. 405 - 407, http://dx.doi.org/10.1111/j.1440-1673.1995.tb00323.x

Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Scitz JF; Harper P; Kerr D; Perez-Manga G; Azab M; Seymour L; Lowery K; Group TTCCS, 1995, '‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia', European Journal of Cancer, 31, pp. 1945 - 1954, http://dx.doi.org/10.1016/0959-8049(95)00502-1

Pryor K; Goddard JD; Goldstein D; Stricker PD; Russell PJ; Golovsky D; Penny R, 1995, 'Bacillus Calmette-Guerein (BCG) enhances mobocyte-and lymphocyte-mediated bladder tumour cell killilng', British Journal of Cancer, 71, pp. 801 - 807, http://dx.doi.org/10.1038/bjc.1995.155

Dear A; Goldstein D; Salem H, 1995, 'pulmonary chronic lymphocytic leukaemia: difficulty in establishing a tissue diagnosis', European Journal of Haematology, pp. 130 - 133

FRIEDLANDER M; LEWIS C; GOLDSTEIN D, 1994, 'UNTITLED', MEDICAL JOURNAL OF AUSTRALIA, 161, pp. 638 - 638

Tindall B; Forde S; Ross MW; Goldstein D; Barker S; Cooper DA, 1994, 'Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine', Patient Education and Counseling, 24, pp. 261 - 266, http://dx.doi.org/10.1016/0738-3991(94)90069-8

Kaldor J; Elford J; Grulich A; Goldstein D, 1994, 'HIV AIDS and cancer', Cancer Forum, 18, pp. 3 - 11

Tindall B; Forde S; Goldsten D; Ross MW; Cooper DA, 1994, 'Sexual dysfunction in advanced HIV disease', AIDS Care, 6, pp. 105 - 107, http://dx.doi.org/10.1080/09540129408258030

Mackintosh JF; Friedlander M; Lewis C; Goldstein D; Herrmann RP; Kearsley JH, 1994, 'Wanted: Guidelines for 'palliative' anti-cancer drug use [3]', Medical Journal of Australia, 161, pp. 638 - 639, http://dx.doi.org/10.5694/j.1326-5377.1994.tb127659.x

GOLDSTEIN D; MILLIKEN S NM; LEWIS C; HOY J; THOMSON B; DOLAN G; RYAN S; SARR A; COOPER DA, 1994, 'FILGRASTIM (r-metHuG-CSF, Amgen), CEOP AND ANTIRETROVIRAL THERAPY IN HIV- RELATED NON-HODGKINS LYMPHOMA (NHL)', AIDS, 8, pp. S46 - S46, http://dx.doi.org/10.1097/00002030-199411004-00179

D G; E T; D C; H G; M N; P H; M O; S M; S P; D H; D C, 1994, 'PHASE I A/B TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER IN ASYMPTOMATIC HTV POSITIVE INDIVIDUALS', AIDS, 8, pp. S14 - S14, http://dx.doi.org/10.1097/00002030-199411004-00054

Tindall B; Carr A; Goldstein D; Penny R; Cooper DA, 1993, 'Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response [1]', AIDS, 7, pp. 127 - 128, http://dx.doi.org/10.1097/00002030-199301000-00020

Lewis CR; Segelov E; Goldstein D; Friedlander ML, 1993, 'Chemotherapy made easier.', Australian and New Zealand Journal of Medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x

Nolten WE; Goldstein D; Lindstrom M; Mckenna MV; Carlson IH; Trump DL; Schiller J; Borden EC; Ehrlich EN, 1993, 'Effects of Cytokines on the Pituitary–Adrenal Axis in Cancer Patients', Journal of Interferon Research, 13, pp. 349 - 357, http://dx.doi.org/10.1089/jir.1993.13.349

Gibson DFC; Johnson DA; Goldstein D; Langan-Fahey SM; Borden EC; Jordan VC, 1993, 'Human recombinant interferon-βSER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse', Breast Cancer Research and Treatment, 25, pp. 141 - 150, http://dx.doi.org/10.1007/BF00662139

GOLDSTEIN D; KAUFMANN M, 1992, 'NOVEL APPROACHES TO THE MANAGEMENT OF GYNECOLOGIC MALIGNANCIES - CHAIRMENS PREFACE - PROCEEDINGS OF A SATELLITE SYMPOSIUM HELD IN CAIRNS, AUSTRALIA, ON 22 SEPTEMBER 1991', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2, pp. 1 - 1, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1992KF21500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smalley RV; Goldstein D; Bulkowski D; Hannon C; Buchler D; Knudsen C; Tuttle RL, 1992, 'A phase II study of crisnatol mesylate in patients with ovarian carcinoma', Investigational New Drugs, 10, pp. 107 - 112, http://dx.doi.org/10.1007/BF00873127

Witt PL; Goldstein D; Storer BE; Grossberg SE; Flashner M; Colby CB; Borden EC, 1992, 'Absence of Biological Effects of Orally Administered Interferon-βser', Journal of Interferon Research, 12, pp. 411 - 413, http://dx.doi.org/10.1089/jir.1992.12.411

Greiner JW; Guadagni F; Goldstein D; Smalley RV; Borden EC; Simpson JF; Molinolo A; Schlom J, 1992, 'Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells', Journal of Clinical Oncology, 10, pp. 735 - 746

Greiner JW; Guadagni F; Goldstein D; Borden EC; Ritts RE; Witt P; LoBuglio AF; Saleh MN; Schlom J, 1991, 'Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons', Cancer Research, 51, pp. 4155 - 4163

Goldstein D; Lewis C, 1991, 'Advances in drug delivery and targeting', Current Opinion in Oncology, 3, pp. 1096 - 1104, http://dx.doi.org/10.1097/00001622-199112000-00019

Goldstein D; O'Leary M; Mitchen J; Borden EC; Wilding G, 1991, 'Effects of interferon βser and transforming growth factor β on prostatic cell lines', Journal of Urology, 146, pp. 1173 - 1177, http://dx.doi.org/10.1016/S0022-5347(17)38034-5

Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR; Leung PE; Levitt D; Sondel PM, 1991, 'Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinom', Cancer Investigation, 9, pp. 35 - 48, http://dx.doi.org/10.3109/07357909109032798

Robinson SP; Goldstein D; Witt PL; Borden EC; Jordan VC, 1990, 'Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-α2', Breast Cancer Research and Treatment, 15, pp. 95 - 101, http://dx.doi.org/10.1007/BF01810781

Goldstein D; Cheuvart B; Trump DL; Shiraki M; Comis RL; Tormey DC; Harris JE; Borden EC, 1990, 'Phase II trial of carboplatin in soft-tissue sarcoma', American Journal of Clinical Oncology Cancer Clinical Trials, 13, pp. 420 - 423, http://dx.doi.org/10.1097/00000421-199010000-00011

Laszlo J; Goldstein D; Gockerman J; Hood L; Huang AT; Triozzi P; Sedwick WD; Koren H; Ellinwood EH; Tso CY, 1990, 'Phase I studies of recombinant interferon-gamma.', J Biol Response Mod, 9, pp. 185 - 193, https://www.ncbi.nlm.nih.gov/pubmed/2160521

Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D, 1989, 'Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.', Cancer Research, 49, pp. 6832 - 6839

Goldstein D; Sielaff KM; Stores BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC, 1989, 'Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-β serine', Journal of the National Cancer Institute, 81, pp. 1061 - 1068, http://dx.doi.org/10.1093/jnci/81.14.1061

Guadagni F; Schlom J; Johnston WW; Szpak CA; Goldstein D; Smalley R; Simpson JF; Borden EC; Pestka S; Greiner JW, 1989, 'Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells', Journal of the National Cancer Institute, 81, pp. 502 - 512, http://dx.doi.org/10.1093/jnci/81.7.502

Goldstein D; Bushmeyer SM; Witt PL; Jordan VC; Borden EC, 1989, 'Effects of Type I and II Interferons on Cultured Human Breast Cells: Interaction with Estrogen Receptors and with Tamoxifen', Cancer Research, 49, pp. 2698 - 2702

Goldstein D; Levi JA; Woods RL; Russell J; Morgan J; Kerestes Z, 1989, 'Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy', Oncology Switzerland, 46, pp. 105 - 108, http://dx.doi.org/10.1159/000226695

Laszlo J; Goldstein D, 1988, 'The doctor's dilemma (the nurse's Waterloo)', Cancer Investigation, 6, pp. 361 - 363, http://dx.doi.org/10.3109/07357908809080660

Goldstein D; Laszlo J, 1988, 'The role of interferon in cancer therapy: A current perspective', CA A Cancer Journal for Clinicians, 38, pp. 258 - 277, http://dx.doi.org/10.3322/canjclin.38.5.258

Triozzi PL; Goldstein D; Laszlo J, 1988, 'Contributions of Benzodiazepines to Cancer Therapy', Cancer Investigation, 6, pp. 103 - 111, http://dx.doi.org/10.3109/07357908809077033

Goldstein D; Kelly R; Ralston M; Penny R; Hayes J, 1987, 'Chemotherapy influencing the course of nephrotic syndrome in colonic carcinoma', Medical Oncology and Tumor Pharmacotherapy, 4, pp. 101 - 105, http://dx.doi.org/10.1007/BF02934947

Goldstein D; Gockerman J; Tso CY; Hood LE, 1987, 'Effects of 7-Interferon on the Endocrine System: Results from a Phase I Study', Cancer Research, 47, pp. 6397 - 6401

Goldstein D; Laszlo J, 1986, 'Interferon Therapy in Cancer: From Imaginon to Interferon', Cancer Research, 46, pp. 4315 - 4329

Geczy CL; Ryan J; Walsh J; Goldstein D, 1986, 'Lymphokine‐induced monocyte procoagulant activity is depressed in patients with advanced malignancies', International Journal of Cancer, 37, pp. 677 - 682, http://dx.doi.org/10.1002/ijc.2910370506

Laszlo J; Goldstein D; Vugrin D; Hood L; Tso CY, 1986, 'Does maintenance therapy with alpha interferon stabilize cancer growth? A pilot study.', J Biol Response Mod, 5, pp. 294 - 299, https://www.ncbi.nlm.nih.gov/pubmed/3734845

Conference Papers

LaFleur J; Hultquist K; Goldstein D; Jogineedi R, 2025, 'Evaluation of a Prototype Hydronic Shell Integrated Envelope and Mechanical Solution', in ASHRAE TRANSACTIONS 2024, VOL 131, PT 1, AMER SOC HEATING, REFRIGERATING AND AIR-CONDITIONING ENGS, FL, Orlando, pp. 90 - 97, presented at 2025 ASHRAE Transactions Conference, FL, Orlando, 08 February 2025 - 12 February 2025, http://dx.doi.org/10.63044/w25laf11

Tan S; Park SB; King T; Kiernan MC; Goldstein D; Li T, 2025, '3569 Characterising the clinical, functional and neurophysiological features of bortezomib induced peripheral neuropathy', in Poster Abstracts, BMJ Publishing Group Ltd, pp. A44.1 - A44, presented at ANZAN Annual Scientific Meeting 2025 Abstracts, http://dx.doi.org/10.1136/bmjno-2025-anzan.119

Vu J; Battaglini E; Li T; Wyld D; Henderson R; Marx G; Krishnan A; Goldstein D; Park SB, 2025, 'CS18 Effect of duloxetine on neuropathic symptom burden and objective neurophysiological parameters in chemotherapy-induced peripheral neuropathy: a crossover randomised controlled trial', in Concurrent Session Abstracts, BMJ Publishing Group Ltd, pp. A10.3 - A11, presented at ANZAN Annual Scientific Meeting 2025 Abstracts, http://dx.doi.org/10.1136/bmjno-2025-anzan.26

Vu J; Battaglini E; Li T; Wyld D; Henderson R; Marx G; Krishnan A; Goldstein D; Park S, 2025, 'Effect of Duloxetine on Quality of Life of Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy: A Crossover Randomised Controlled Trial', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY

Sandler CX; Goldstein D; Ee C; Vuong K; Jones M; Clifford B; Serafimovska A; Polykarpou N; Khair R; Lloyd A, 2025, 'IGNITE: Development and Evaluation of Patient, General Practitioner and Allied Health Professional eLearning to Facilitate Care for Post-Cancer Fatigue', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY

Li T; Harden C; Goldstein D; Timmins H; Horvath L; Kiernan M; Park S, 2025, 'Longitudinal Changes in Axonal Excitability and Neurofilament Light Chain in Oxaliplatin Treated Patients', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. 251 - 251

Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; Baron-Hay S; Kiernan MC; Barnes EH; Goldstein D; Park SB, 2024, 'Clinical risk factors associated with development of significant nerve damage during chemotherapy', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 257 - 258

Back to profile page